ArticleCase reports in oncology
Anlotinib plus Chemotherapy for the Treatment of Refractory Primary Cardiac Intimal Sarcoma: A Case Report.
Article in Case reports in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primary cardiac intimal sarcoma (CIS) is a rare and highly malignant soft tissue tumor associated with an extremely poor prognosis. To date, there are no established treatment guidelines for CIS in clinical practice. Case Presentation: A 44-year-old man was diagnosed with left atrial intimal sarcoma. Forty-two days after radical surgical resection, he developed local recurrence accompanied by brain and gluteus medius metastases. The patient first received emergency radiotherapy for intracranial metastases, followed by six cycles of systemic chemotherapy with ifosfamide and epirubicin, combined with targeted therapy using anlotinib. Ultimately, he achieved an overall survival (OS) of 17 months. Conclusion: To our knowledge, this is the first report describing the therapeutic efficacy of anlotinib in CIS. This case highlights the potential role of anlotinib as a promising therapeutic option for this rare and aggressive malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.